Page last updated: 2024-08-23

atomoxetine hydrochloride and Parkinson Disease, Secondary

atomoxetine hydrochloride has been researched along with Parkinson Disease, Secondary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Connor, TJ; Harkin, A; Nolan, YM; O'Neill, E; Yssel, JD	1

Other Studies

1 other study(ies) available for atomoxetine hydrochloride and Parkinson Disease, Secondary

Article	Year
Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease. Brain, behavior, and immunity, 2018, Volume: 69 Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Dopamine; Dopaminergic Neurons; Idazoxan; Lipopolysaccharides; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar; Treatment Outcome	2018

Article

Year

Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease.

Brain, behavior, and immunity, 2018, Volume: 69

Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Brain; Dopamine; Dopaminergic Neurons; Idazoxan; Lipopolysaccharides; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar; Treatment Outcome

2018